Literature DB >> 19328348

Electronystagmography in migraine equivalent syndrome.

Renzo Mora1, Massimo Dellepiane, Luciano Barettini, Barbara Crippa, Angelo Salami.   

Abstract

OBJECTIVES: The aim of the study was to determine the efficacy of electronystagmography testing in the diagnosis of vertigo in children with migraine equivalent syndrome. STUDY
DESIGN: The investigation included 20 children with "migraine equivalent syndrome" (group A), characterized by benign paroxysmal vertigo of childhood. As a control group, 50 healthy children were identified. SUBJECTS AND METHODS: All the subjects underwent rotatory vestibular stimulation by stop test, optokinetic stimulation, and simultaneous postrotatory vestibular and optokinetic stimulations (VVOR).
RESULTS: For the analysis of the results, we considered nystagmus mean gain and direction of visual-vestibular-ocular-reflex (VVOR) nystagmus. In group A, all the children presented a VVOR nystagmus homodirectional to vestibular-ocular reflex (VOR). In the control group, all the subjects presented a VVOR nystagmus homodirectional to optokinetic nystagmus (OKN).
CONCLUSION: In the healthy patients, VVOR nystagmus is always homodirectional to OKN and indicates the optokinetic system prevalence on VOR. The presence of a VVOR nystagmus homodirectional to VOR indicates the absence of the optokinetic system prevalence due to a central nervous system (CNS) modification and highlights a CNS disease. Our data highlight a possible correlation between CNS disorders and migraine equivalent syndrome.

Entities:  

Mesh:

Year:  2009        PMID: 19328348     DOI: 10.1016/j.otohns.2008.12.024

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  1 in total

1.  A study of safety and tolerability of rotatory vestibular input for preschool children.

Authors:  Wen-Ching Su; Chin-Kai Lin; Shih-Chung Chang
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-31       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.